Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 30

Sort by

Sort Order Select

Journal Articles

Real-World Multicenter Evaluation of Venetoclax and Azacitidine for Molecular Relapse after First Line Intensive Chemotherapy in Patients with NPM1 Mutated or Core Binding Factor (CBF) AML. a Filo Study

Blood (2024) 144 (Supplement 1): 58.

https://doi.org/10.1182/blood-2024-205592

Published: 2024

Journal Articles

Dasatinib Overcomes AML Resistance to BCL2 Inhibition By Indirectly Inhibiting MCL1: From Ex Vivo drug Sensitivity/Resistance Profiling to a Phase II Clinical Trial: A Hemato-BIO Study

Sylvain Garciaz, Rémy Castellano, Arnaud Jacquel, Arnaud Guille, Maxence Bourgoin, Camille Montersino, José Adélaïde, Patrick Auberger, Daniel Birnbaum, Marie Anne Hospital, Yves Collette, Norbert Vey

Blood (2024) 144 (Supplement 1): 1378.

https://doi.org/10.1182/blood-2024-207352

Published: 2024

Journal Articles

Results of a Phase 1, First-in-Human Study of INA03, an Anti-CD71 Antibody-Drug Conjugate in Patients with Relapsed or Refractory (R/R) Acute Leukemias

Sylvain Garciaz, Pierre Bories, Jean-Marie Boher, Marie Anne Hospital, Christian Récher, Colombe Saillard, Yosr Hicheri, Renato Monteiro, Olivier Hermine, Pierre Launay, Norbert Vey

Blood (2024) 144 (Supplement 1): 1496.

https://doi.org/10.1182/blood-2024-207436

Published: 2024

Journal Articles

A Phase II Study of Single Agent Aspacytarabine (BST-236) in Adults Unfit for Intensive Chemotherapy with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) or Higher Risk Myelodysplastic Syndromes (R/R HR MDS)

Marie Anne Hospital, Thomas Cluzeau, Alice Garnier, Giovanni Marconi, Emmanuelle Tavernier, Sylvain Thepot, Aspasia Stamatoullas, Cristina Papayannidis, Sophie Park, Noemie Bigot, Lamya AIT SI Selmi, Fatiha Chermat, Sylvie Chevret, Pierre Fenaux

Blood (2023) 142 (Supplement 1): 2923.

https://doi.org/10.1182/blood-2023-185609

Published: 2023

Journal Articles

Current Results of Intensive Therapy in Younger Adults with Acute Myeloid Leukemia (AML): The Large Randomized French Backbone Intergroup (BIG)-1 Study on Behalf of the Filo, ALFA, and SFGM-TC Study Groups

Blood (2023) 142 (Supplement 1): 967.

https://doi.org/10.1182/blood-2023-179376

Published: 2023

Journal Articles

Clinical, Cytogenetic and Molecular Characterization of a 96 MDS and AML Cohort with TP53 Mutation

Blood (2023) 142 (Supplement 1): 6483.

https://doi.org/10.1182/blood-2023-186086

Published: 2023

Journal Articles

Molecular Relapse after First-Line Intensive Therapy in Patients with Core-Binding Factor and NPM1 -Mutated Acute Myeloid Leukemia - a Filo Study

Corentin Orvain, Sarah Bertoli, Pierre Peterlin, Yohan Desbrosses, Pierre-Yves Dumas, Alexandre Iat, Marie Anne Hospital, Martin Carre, Emmanuelle Tavernier, Anne Bouvier, Audrey Bidet, Sylvie Tondeur, Florian Renosi, Eric Delabesse, Arnaud Pigneux, Hunault-Berger Mathilde, Christian Recher

Blood (2023) 142 (Supplement 1): 421.

https://doi.org/10.1182/blood-2023-184848

Published: 2023

Journal Articles

Poor Prognosis of SRSF2 Gene Mutations in Patients Treated with Venetoclax-Azacitidine (VEN-AZA) for Newly Diagnosed Acute Myeloid Leukemia. a Multicentric Real-Life Study of 117 Patients

Blood (2023) 142 (Supplement 1): 2848.

https://doi.org/10.1182/blood-2023-180733

Published: 2023

Journal Articles

FLT3 Ligand Kinetic Profile Predicts Response to Treatment and Event-Free Survival (EFS) in Adults with High-Risk MDS/CMML Receiving CPX-351: A GFM Study

Pierre Peterlin, Joëlle Gaschet, Pascal Turlure, Marie-Pierre Gourin, Pierre-Yves Dumas, Sylvain Thepot, Ana Berceanu, Sophie Park, Marie Anne Hospital, Thomas Cluzeau, Jose-Miguel Torregrosa-Diaz, Louis Drevon, Rosa Sapena, Fatiha Chermat, Sophie Dimicoli-Salazar, Maxime Jullien, Pierre Fenaux, Patrice Chevallier

Blood (2023) 142 (Supplement 1): 6469.

https://doi.org/10.1182/blood-2023-173741

Published: 2023

Journal Articles

Acute Myeloid Leukemia Patients Who Stopped Venetoclax or/and Azacytidine for Other Reasons Than Progression Have a Prolonged Treatment Free Remission and Overall Survival. a Filo Study

Sylvain Garciaz, Sarah Bertoli, David A Sallman, Justine Decroocq, Pierre-Yves Dumas, Amine Belhabri, Corentin Orvain, Gaspar Aspas Requena, Celestine Simand, Kamel Laribi, Martin Carré, Alberto Santagostino, Ludovic Gabellier, Marie Anne Hospital, Ariane Mineur, Arnaud Pigneux, Norbert Vey, Christian Récher

Blood (2023) 142 (Supplement 1): 161.

https://doi.org/10.1182/blood-2023-185437

Published: 2023

Journal Articles

Preliminary Results of a Phase 1, First-in-Human Study of INA03, an Anti-CD71 Antibody-Drug Conjugate in Patients with Relapsed or Refractory (R/R) Acute Leukemias

Sylvain Garciaz, Pierre Bories, Jean-Marie Boher, Marie Anne Hospital, Christian Récher, Colombe Saillard, Yosr Hicheri, Coralie Belanger, Renato Monteiro, Olivier Hermine, Pierre Launay, Norbert Vey

Blood (2023) 142 (Supplement 1): 4290.

https://doi.org/10.1182/blood-2023-185717

Published: 2023

Journal Articles

Gilteritinib Activity in Refractory or Relapsed FLT3 -Mutated Acute Myeloid Leukemia Patients Previously Treated By Intensive Chemotherapy and Midostaurin: A Study from the French AML Intergroup ALFA/Filo

Blood (2022) 140 (Supplement 1): 8996–8998.

https://doi.org/10.1182/blood-2022-159125

Published: 2022

Journal Articles

Long-Term Survival of Acute Myeloid Leukemia Responding Patients Who Stopped Azacytidine and/or Venetoclax Because of Poor Tolerance or Physician Choice: A Retrospective Multicenter Study from the French Innovative Leukemia Organization (FILO)

Sylvain Garciaz, Justine Decroocq, Sarah Bertoli, Amine Belhabri, Pierre-Yves Dumas, Celestine Simand, Kamel Laribi, Alberto Santagostino, Martin Carre, Aline Schmidt, Gaspard Aspas Requena, Chantal Himberlin, Marie-Anne Hospital, Christian Recher, Norbert Vey

Blood (2022) 140 (Supplement 1): 6147–6148.

https://doi.org/10.1182/blood-2022-158247

Published: 2022

Journal Articles

Molecular Response Analysis By High Throughput Sequencing in Higher Risk Myelodysplastic Syndrome (HR-MDS) Treated Intensively with CPX-351

Blood (2022) 140 (Supplement 1): 9821–9823.

https://doi.org/10.1182/blood-2022-162278

Published: 2022

Journal Articles

Feasibility of Cellular Therapies in HIV Infected Patients: A Monocentric Retrospective Analysis

Luca Inchiappa, Gabriel Brisou, Benjamin Bouchacourt, Samia Harbi, Faezeh Legrand, Raynier Devillier, Hélène Laroche, Olivia Faucher, Sylvie Bregigeon, Christian Chabannon, Marie-Anne Hospital, Norbert Vey, Didier Blaise, Sabine Furst

Blood (2022) 140 (Supplement 1): 12959–12960.

https://doi.org/10.1182/blood-2022-167144

Published: 2022

Journal Articles

CPX 351 As First Line Treatment in Higher Risk MDS. a Phase II Trial By the GFM

Pierre Peterlin, Pascal Turlure, Patrice Chevallier, Marie-Pierre Gourin, Pierre-Yves Dumas, Sylvain Thepot, Anna Berceanu, Sophie Park, Marie Anne Hospital, Thomas Cluzeau, Jose Miguel Torregrosa Diaz, Louis Devron, Sylvie Chevret, Marie C Bene, Yannick Le Bris, Rosa Sapena, Fatiha Chermat, Sophie Dimicoli-Salazar, Pierre Fenaux

Blood (2021) 138 (Supplement 1): 243.

https://doi.org/10.1182/blood-2021-145123

Published: 2021

Journal Articles

IDH Mutations Identify a Subgroup of NPM1 Patients with a More Favorable Prognosis. a Retrospective Multicenter Study of the Filo Group

Sylvain Garciaz, Marie Anne Hospital, Colombe Saillard, MD, Yosr Hicheri, Evelyne D'Incan, Jerome Rey, Catherine Lacombe, Arnaud Pigneux, MD PhD, Marie-Christine Béné, PharmSciD, PhD, Christian Recher, MD PhD, Marie-Joelle Mozziconacci, Norbert Vey, MD

Blood (2020) 136 (Supplement 1): 39–40.

https://doi.org/10.1182/blood-2020-141229

Published: 2020

Journal Articles

Long Term Analysis of a Monocentric Cohort of Therapy-Related Acute Lymphoblastic Leukemia

Sylvain Garciaz, Amel Soua, Ilhem Rahal, Marie Anne Hospital, Colombe Saillard, MD, Yosr Hicheri, Bilal Mohty, MD, Evelyne D'Incan, Jerome Rey, MD, Norbert Vey, MD

Blood (2020) 136 (Supplement 1): 23.

https://doi.org/10.1182/blood-2020-139918

Published: 2020

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation in Patients of 65 Years or Older: A Monocenter Analysis on 252 Patients

Blood (2019) 134 (Supplement_1): 4625.

https://doi.org/10.1182/blood-2019-131845

Published: 2019

Journal Articles

Cegal Protocol : Evaluation of the Feasibility of a Chemogenomic Approach to Identify Personalized Therapy for Relapse or Refractory AML Patients

Norbert Vey, MD PhD, Marie Anne Hospital, Aude Collignon, Yves Collette, Daniel Birnbaum, Aude Charbonnier, Bilal Mohty, MD, Evelyne D'Incan, Jerome Rey, Remy Castellano, Camille Montersino, Max Chaffanet, Nadine Carbuccia, Jose Adelaide, Benjamin Bouchacourt, Arnaud Guille

Blood (2018) 132 (Supplement 1): 1401.

https://doi.org/10.1182/blood-2018-99-119263

Published: 2018

NARROW

Real-World Multicenter Evaluation of Venetoclax and Azacitidine for Molecular Relapse after First Line Intensive Chemotherapy in Patients with NPM1 Mutated or Core Binding Factor (CBF) AML. a Filo Study

Dasatinib Overcomes AML Resistance to BCL2 Inhibition By Indirectly Inhibiting MCL1: From Ex Vivo drug Sensitivity/Resistance Profiling to a Phase II Clinical Trial: A Hemato-BIO Study

Results of a Phase 1, First-in-Human Study of INA03, an Anti-CD71 Antibody-Drug Conjugate in Patients with Relapsed or Refractory (R/R) Acute Leukemias

A Phase II Study of Single Agent Aspacytarabine (BST-236) in Adults Unfit for Intensive Chemotherapy with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) or Higher Risk Myelodysplastic Syndromes (R/R HR MDS)

Current Results of Intensive Therapy in Younger Adults with Acute Myeloid Leukemia (AML): The Large Randomized French Backbone Intergroup (BIG)-1 Study on Behalf of the Filo, ALFA, and SFGM-TC Study Groups

Clinical, Cytogenetic and Molecular Characterization of a 96 MDS and AML Cohort with TP53 Mutation

Molecular Relapse after First-Line Intensive Therapy in Patients with Core-Binding Factor and NPM1 -Mutated Acute Myeloid Leukemia - a Filo Study

Poor Prognosis of SRSF2 Gene Mutations in Patients Treated with Venetoclax-Azacitidine (VEN-AZA) for Newly Diagnosed Acute Myeloid Leukemia. a Multicentric Real-Life Study of 117 Patients

FLT3 Ligand Kinetic Profile Predicts Response to Treatment and Event-Free Survival (EFS) in Adults with High-Risk MDS/CMML Receiving CPX-351: A GFM Study

Acute Myeloid Leukemia Patients Who Stopped Venetoclax or/and Azacytidine for Other Reasons Than Progression Have a Prolonged Treatment Free Remission and Overall Survival. a Filo Study

Preliminary Results of a Phase 1, First-in-Human Study of INA03, an Anti-CD71 Antibody-Drug Conjugate in Patients with Relapsed or Refractory (R/R) Acute Leukemias

Gilteritinib Activity in Refractory or Relapsed FLT3 -Mutated Acute Myeloid Leukemia Patients Previously Treated By Intensive Chemotherapy and Midostaurin: A Study from the French AML Intergroup ALFA/Filo

Long-Term Survival of Acute Myeloid Leukemia Responding Patients Who Stopped Azacytidine and/or Venetoclax Because of Poor Tolerance or Physician Choice: A Retrospective Multicenter Study from the French Innovative Leukemia Organization (FILO)

Molecular Response Analysis By High Throughput Sequencing in Higher Risk Myelodysplastic Syndrome (HR-MDS) Treated Intensively with CPX-351

Feasibility of Cellular Therapies in HIV Infected Patients: A Monocentric Retrospective Analysis

CPX 351 As First Line Treatment in Higher Risk MDS. a Phase II Trial By the GFM

IDH Mutations Identify a Subgroup of NPM1 Patients with a More Favorable Prognosis. a Retrospective Multicenter Study of the Filo Group

Long Term Analysis of a Monocentric Cohort of Therapy-Related Acute Lymphoblastic Leukemia

Allogeneic Hematopoietic Stem Cell Transplantation in Patients of 65 Years or Older: A Monocenter Analysis on 252 Patients

Cegal Protocol : Evaluation of the Feasibility of a Chemogenomic Approach to Identify Personalized Therapy for Relapse or Refractory AML Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only